This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collard, C. D. Articles by Stahl, G. L. Search for Related Content PubMed PubMed Citation Articles by Collard, C. D. Articles by Stahl, G. L. Related Collections Endothelium/vascular type/nitric oxide Pathophysiology Cell biology/structural biology

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:2623.)
© 1999 American Heart Association, Inc.

Vascular Biology

Endothelial Nuclear Factor-B Translocation and Vascular Cell Adhesion Molecule-1 Induction by Complement

Inhibition With Anti-Human C5 Therapy or cGMP Analogues

Charles D. Collard; Azin Agah; Wende Reenstra; Jon Buras; Gregory L. Stahl
Abstract—We have previously shown that reoxygenation of hypoxic human umbilical vein endothelial cells (HUVECs) leads to the activation and deposition of complement. In the present study, we investigated whether the terminal complement complex (C5b-9) influences HUVEC nuclear factor-B (NF-B) translocation and vascular cell adhesion molecule-1 (VCAM-1) protein expression after hypoxia/reoxygenation by decreasing endothelial cGMP. Additionally, we investigated the action of anti-human C5 therapy on endothelial cGMP, NF-B translocation, and VCAM-1 protein expression. Reoxygenation (0.5 to 3 hours, 21% O₂) of hypoxic (12 hours, 1% O₂) HUVECs in human serum (HS) significantly increased C5b-9 deposition, VCAM-1 expression, and NF-B translocation compared with hypoxic/reoxygenated HUVECs treated with the recombinant human C5 inhibitor h5G1.1-scFv. Acetylcholine (ACh)-induced cGMP synthesis was significantly higher in normoxic HUVECs compared with hypoxic HUVECs reoxygenated in HS but did not differ from hypoxic HUVECs reoxygenated in buffer or HS treated with h5G1.1-scFv. Treatment of hypoxic/reoxygenated HUVECs with h5G1.1-scFv or cGMP analogues significantly attenuated NF-B translocation and VCAM-1 protein expression. Treatment with NO analogues, but not a cAMP analogue, cGMP antagonists, or an NO antagonist, also significantly attenuated VCAM-1 expression. We conclude that (1) C5b-9 deposition, NF-B translocation, and VCAM-1 protein expression are increased in hypoxic HUVECs reoxygenated in HS; (2) reoxygenation of hypoxic HUVECs in HS, but not buffer alone, attenuates ACh-induced cGMP synthesis; and (3) treatment of hypoxic/reoxygenated HUVECs with h5G1.1-scFv attenuates C5b-9 deposition, NF-B translocation, and VCAM-1 expression while preserving ACh-induced cGMP synthesis. C5b-9–induced VCAM-1 expression may thus involve an NO/cGMP-regulated NF-B translocation mechanism.

Key Words: adhesion molecules • hypoxia • inflammation • nitric oxide • immunotherapy

This article has been cited by other articles:

				F. Qiao, C. Atkinson, H. Song, R. Pannu, I. Singh, and S. Tomlinson Complement Plays an Important Role in Spinal Cord Injury and Represents a Therapeutic Target for Improving Recovery following Trauma Am. J. Pathol., September 1, 2006; 169(3): 1039 - 1047. [Abstract] [Full Text] [PDF]

				E. Vellaichamy, M. L. Khurana, J. Fink, and K. N. Pandey Involvement of the NF-{kappa}B/Matrix Metalloproteinase Pathway in Cardiac Fibrosis of Mice Lacking Guanylyl Cyclase/Natriuretic Peptide Receptor A J. Biol. Chem., May 13, 2005; 280(19): 19230 - 19242. [Abstract] [Full Text] [PDF]

				A. J. Chong, C. R. Hampton, and E. D. Verrier Microvascular Inflammatory Response in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 333 - 354. [Abstract] [PDF]

				M. C. Montalto, M. L. Hart, J. E. Jordan, K. Wada, and G. L. Stahl Role for complement in mediating intestinal nitric oxide synthase-2 and superoxide dismutase expression Am J Physiol Gastrointest Liver Physiol, June 9, 2003; 285(1): G197 - G206. [Abstract] [Full Text] [PDF]

				J. E. Jordan, M. C. Montalto, and G. L. Stahl Inhibition of Mannose-Binding Lectin Reduces Postischemic Myocardial Reperfusion Injury Circulation, September 18, 2001; 104(12): 1413 - 1418. [Abstract] [Full Text] [PDF]

				M. C. Montalto, C. D. Collard, J. A. Buras, W. R. Reenstra, R. McClaine, D. R. Gies, R. P. Rother, and G. L. Stahl A Keratin Peptide Inhibits Mannose-Binding Lectin J. Immunol., March 15, 2001; 166(6): 4148 - 4153. [Abstract] [Full Text] [PDF]

				R. Lekowski, C. D. Collard, W. R. Reenstra, and G. L. Stahl Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation Protein Sci., February 1, 2001; 10(2): 277 - 284. [Abstract] [Full Text]

				A. Agah, M. C. Montalto, C. L. Kiesecker, M. Morrissey, M. Grover, K. L. Whoolery, R. P. Rother, and G. L. Stahl Isolation, Characterization, and Cloning of Porcine Complement Component C7 J. Immunol., July 15, 2000; 165(2): 1059 - 1065. [Abstract] [Full Text] [PDF]

				C. D. Collard, A. Vakeva, M. A. Morrissey, A. Agah, S. A. Rollins, W. R. Reenstra, J. A. Buras, S. Meri, and G. L. Stahl Complement Activation after Oxidative Stress : Role of the Lectin Complement Pathway Am. J. Pathol., May 1, 2000; 156(5): 1549 - 1556. [Abstract] [Full Text] [PDF]